View More
Learn from expert faculty what key clinical considerations inform the use of biosimilars in oncology practice with this series of ClinicalThought™ commentaries!
How do biosimilars compare with reference biologics and small-molecule compounds? Here’s my take.
Rowena N. Schwartz, PharmD, BCOP
Physicians:
maximum of 0.25 AMA PRA Category 1 Credits™
Registered Nurses:
0.2 Nursing contact hours
Pharmacists:
0.25 contact hours (0.025 CEUs)
Released: November 14, 2018
Expired:
No longer available for credit
Here’s my take on why some of the key reasons biosimilars may be an attractive cost-cutting measure in cancer care also pose a challenge to their widespread adoption.
Gary H. Lyman, MD, MPH, FASCO, FACP, FRCP
Physicians:
maximum of 0.25 AMA PRA Category 1 Credits™
Registered Nurses:
0.2 Nursing contact hours
Pharmacists:
0.25 contact hours (0.025 CEUs)
Released: December 18, 2018
Expired:
No longer available for credit
Herein, I summarize recent biosimilar approvals as well as how these agents might affect patient care and counseling in oncology practice.
Jeffrey Crawford, MD
Physicians:
maximum of 0.25 AMA PRA Category 1 Credits™
Registered Nurses:
0.2 Nursing contact hours
Pharmacists:
0.25 contact hours (0.025 CEUs)
Released: January 18, 2019
Expired:
No longer available for credit
Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112
Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)
ahughes@pimed.com
www.pimed.com
You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.